Literature DB >> 1766669

Repression of the chicken c-rel promoter by vRel in chicken embryo fibroblasts is not mediated through a consensus NF-kappa B binding site.

A J Capobianco1, T D Gilmore.   

Abstract

To understand the regulation of expression of the chicken c-rel gene, we cloned genomic sequences upstream of the start site of transcription of c-rel. Sequence analysis shows that the c-rel promoter is a GC-rich promoter that lacks a TATA box. In addition, there are putative binding sites for several transcription factors, including an NF-kappa B consensus binding site. Primer extension showed that there is one major start site (site 1) for transcription in chicken embryo fibroblasts and two major start sites in a v-rel-transformed chicken spleen cell line. In transient assays using c-rel promoter sequences and the CAT reporter gene, we found that vRel repressed expression from the c-rel promoter. Other viral oncoproteins and a non-transforming v-rel deletion mutant did not repress the c-rel promoter. Repression occurred through sequences located within 125 bp of the start of transcription. However, mutation of the consensus NF-kappa B binding site did not affect the level of transcription from the c-rel promoter, nor did it interfere with repression by vRel, even though vRel could bind to the wild-type, but not the mutant, version of this sequence in vitro. These results suggest that the vRel protein can repress transcription through an indirect mechanism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1766669

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1992-08-11       Impact factor: 16.971

2.  Interaction of the v-Rel oncoprotein with NF-kappaB and IkappaB proteins: heterodimers of a transformation-defective v-Rel mutant and NF-2 are functional in vitro and in vivo.

Authors:  D W White; G A Pitoc; T D Gilmore
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

3.  Temperature-sensitive transforming mutants of the v-rel oncogene.

Authors:  D W White; T D Gilmore
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

4.  NF-kappa B p100 is one of the high-molecular-weight proteins complexed with the v-Rel oncoprotein in transformed chicken spleen cells.

Authors:  S Sif; T D Gilmore
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

5.  The relocalization of v-Rel from the nucleus to the cytoplasm coincides with induction of expression of Ikba and nfkb1 and stabilization of I kappa B-alpha.

Authors:  R Hrdlicková; J Nehyba; A Roy; E H Humphries; H R Bose
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

6.  Structural and functional characterization of the promoter regions of the NFKB2 gene.

Authors:  L Lombardi; P Ciana; C Cappellini; D Trecca; L Guerrini; A Migliazza; A T Maiolo; A Neri
Journal:  Nucleic Acids Res       Date:  1995-06-25       Impact factor: 16.971

7.  p105, the NF-kappa B p50 precursor protein, is one of the cellular proteins complexed with the v-Rel oncoprotein in transformed chicken spleen cells.

Authors:  A J Capobianco; D Chang; G Mosialos; T D Gilmore
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

8.  GAL4-I kappa B alpha and GAL4-I kappa B gamma activate transcription by different mechanisms.

Authors:  P J Morin; G S Subramanian; T D Gilmore
Journal:  Nucleic Acids Res       Date:  1993-05-11       Impact factor: 16.971

9.  Mutations in the DNA-binding and dimerization domains of v-Rel are responsible for altered kappa B DNA-binding complexes in transformed cells.

Authors:  R Hrdlicková; J Nehyba; H R Bose
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

10.  Hormone-regulated v-rel estrogen receptor fusion protein: reversible induction of cell transformation and cellular gene expression.

Authors:  G Boehmelt; A Walker; N Kabrun; G Mellitzer; H Beug; M Zenke; P J Enrietto
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.